Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences

What: Abbott Laboratories (ABT) has completed its acquisition of Exact Sciences, a leading cancer diagnostics company.
Why: The acquisition is expected to enhance Abbott's presence in the cancer diagnostics market, expanding its portfolio of non-invasive tests.
Signal: Shares of ABT have risen **5.2%** in pre-market trading, indicating a positive market reaction to the news.
Target: The acquisition is expected to close in the second quarter of 2026, with the companies aiming to achieve **$1.5 billion** in cost synergies by 2028.
Risk: The integration of Exact Sciences' operations may pose risks to Abbott's financial performance, particularly if the company fails to realize expected cost synergies.